Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI

被引:39
作者
Quarles, C. C.
Schmainda, K. M.
机构
[1] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA
关键词
anti-angiogenic therapy; tumor perfusion; DSC-MRI; brain tumor;
D O I
10.1002/mrm.21193
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To investigate the influence of anti-angiogenic agents on tumor perfusion, we employed a dynamic susceptibility contrast (DSC)-MRI method that utilizes a simultaneous gradient-echo (GE) and spin-echo (SE) imaging sequence to derive perfusion parameters (blood flow, blood volume, and mean transit time (MTT)). These parameters are sensitive to both the total vasculature (from the GE data) and the microvasculature (from the SE data), and can also provide a measure of the mean vessel diameter (mVD). This approach was used to evaluate the response of a 9L rat brain tumor model to 20 mg/kg and 40 mg/kg of the anti-angiogenic agent SU11657. The 20-mg/kg dose significantly decreased mVD by 29.9% (P=0.02). The 40-mg/kg dose significantly decreased mVD by 30.4% (P=0.0007), SE blood volume by 31.8% (P=0.03), GE and SE MTT by 46.9% (P=0.03) and 62.0% (P=0.0005), and increased GE and SE blood flow by 36.6% (P=0.04) and 52.6% (P=0.02). These findings demonstrate that DSC-MRI perfusion methods can play a key role in the noninvasive evaluation of morphological and functional changes in tumor vasculature in response to therapy.
引用
收藏
页码:680 / 687
页数:8
相关论文
共 43 条
[1]  
Abrams TJ, 2003, MOL CANCER THER, V2, P1011
[2]   Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor [J].
Albert, DH ;
Tapang, P ;
Magoc, TJ ;
Pease, LJ ;
Reuter, DR ;
Wei, RQ ;
Li, JL ;
Guo, J ;
Bousquet, PF ;
Ghoreishi-Haack, NS ;
Wang, B ;
Bukofzer, GT ;
Wang, YC ;
Stavropoulos, JA ;
Hartandi, K ;
Niquette, AL ;
Soni, N ;
Johnson, EF ;
McCall, JO ;
Bouska, JJ ;
Luo, Y ;
Donawho, CK ;
Dai, YJ ;
Marcotte, PA ;
Glaser, KB ;
Michaelides, MR ;
Davidsen, SK .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :995-1006
[3]  
ANSIAUX R, 2004, P 11 ANN M ISMRM KYO, P2004
[4]   CEREBRAL BLOOD-VOLUME MAPS OF GLIOMAS - COMPARISON WITH TUMOR GRADE AND HISTOLOGIC-FINDINGS [J].
ARONEN, HJ ;
GAZIT, IE ;
LOUIS, DN ;
BUCHBINDER, BR ;
PARDO, FS ;
WEISSKOFF, RM ;
HARSH, GR ;
COSGROVE, GR ;
HALPERN, EF ;
HOCHBERG, FH ;
ROSEN, BR .
RADIOLOGY, 1994, 191 (01) :41-51
[5]   The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice [J].
Bäckman, U ;
Christofferson, R .
PEDIATRIC RESEARCH, 2005, 57 (05) :690-695
[6]   Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps [J].
Badruddoja, MA ;
Krouwer, HGJ ;
Rand, SD ;
Rebro, KJ ;
Pathak, AP ;
Schmainda, KM .
NEURO-ONCOLOGY, 2003, 5 (04) :235-243
[7]   MR CONTRAST DUE TO INTRAVASCULAR MAGNETIC-SUSCEPTIBILITY PERTURBATIONS [J].
BOXERMAN, JL ;
HAMBERG, LM ;
ROSEN, BR ;
WEISSKOFF, RM .
MAGNETIC RESONANCE IN MEDICINE, 1995, 34 (04) :555-566
[8]   MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report [J].
Brasch, R ;
Turetschek, K .
EUROPEAN JOURNAL OF RADIOLOGY, 2000, 34 (03) :148-155
[9]  
Browder T, 2000, CANCER RES, V60, P1878
[10]   NMR imaging of changes in vascular morphology due to tumor angiogenesis [J].
Dennie, J ;
Mandeville, JB ;
Boxerman, JL ;
Packard, SD ;
Rosen, BR ;
Weisskoff, RM .
MAGNETIC RESONANCE IN MEDICINE, 1998, 40 (06) :793-799